SeaStar Medical Holding Corporation ICU

Company Overview

SeaStar Medical Holding Corporation is a U.S.-based medical technology company focused on developing extracorporeal therapies designed to reduce the consequences of excessive inflammation in critically ill patients. The company operates within the biotechnology, medical device, and critical care healthcare industries, with a primary emphasis on therapies targeting hyperinflammation associated with acute kidney injury (AKI), sepsis, and other life-threatening inflammatory conditions. Its core technology platform centers on the Selective Cytopheretic Device (SCD), a cell-directed immunomodulatory therapy intended to selectively target activated immune cells during extracorporeal blood circulation.

The company’s principal revenue and development driver has been the advancement and commercialization efforts surrounding the QUELIMMUNE therapy platform and related SCD technologies. SeaStar Medical primarily serves hospitals, intensive care units, pediatric critical care providers, and nephrology-focused treatment centers. The company traces its origins to research into immune modulation and extracorporeal blood purification technologies and later became publicly traded through a business combination transaction involving a special purpose acquisition company (SPAC). Its strategic positioning is tied to addressing unmet medical needs in critically ill patient populations where treatment options remain limited and mortality rates are high.

Business Operations

SeaStar Medical conducts its operations primarily through the development, regulatory advancement, and commercialization of immunomodulatory medical devices. The company’s primary operating focus is its SCD therapy platform, which is designed for use alongside continuous kidney replacement therapy systems in critically ill patients. Revenue generation has historically been limited due to the company’s clinical-stage profile, with operations primarily supported through financing activities, capital raises, and strategic development initiatives rather than broad commercial sales. Public filings indicate that regulatory approvals and expanded commercialization represent major future revenue objectives.

Operationally, the company is concentrated in the United States, where it manages clinical development, regulatory engagement with the U.S. Food and Drug Administration (FDA), and commercialization planning. SeaStar Medical controls intellectual property associated with the SCD platform and related therapeutic applications. The company has collaborated with clinical institutions and healthcare providers involved in critical care and nephrology research. Public disclosures also reference relationships with manufacturing and development partners supporting device production and clinical operations. Data regarding extensive international subsidiaries or large-scale joint ventures remains limited based on available public sources.

Strategic Position & Investments

SeaStar Medical’s strategic direction is centered on expanding the clinical and commercial adoption of its immunomodulatory therapies for critically ill patients experiencing hyperinflammatory conditions. A major strategic milestone was the FDA-related progress involving QUELIMMUNE, which was developed for pediatric acute kidney injury patients with sepsis or septic conditions requiring continuous kidney replacement therapy. The company has emphasized continued clinical development programs aimed at broader adult indications, including AKI and systemic inflammatory disorders.

The company’s investments have largely focused on clinical trials, regulatory approvals, manufacturing scale-up, and intellectual property development tied to the Selective Cytopheretic Device platform. SeaStar Medical has also highlighted opportunities in emerging areas of precision immunomodulation and extracorporeal therapeutic technologies. While the company remains relatively small compared with major medical device manufacturers, its differentiation strategy is based on targeting dysregulated immune responses rather than conventional filtration-only blood purification approaches. Publicly available information does not indicate a broad portfolio of acquired operating companies or extensive investment holdings outside its core therapeutic platform.

Geographic Footprint

SeaStar Medical is headquartered in Denver, Colorado, and its operational footprint is primarily concentrated in the United States. Clinical development activities, regulatory interactions, and commercialization efforts have predominantly involved U.S.-based hospitals, healthcare systems, and medical research institutions. The company’s market focus currently centers on North American critical care and nephrology markets due to FDA-driven regulatory pathways and commercialization priorities.

Although SeaStar Medical’s technology addresses medical conditions with global relevance, publicly available information indicates limited direct international commercial operations at this stage. The company’s therapeutic platform may have potential applicability across broader international healthcare markets, particularly in regions with advanced critical care infrastructure, but current operational influence outside the United States appears limited. Data regarding material international subsidiaries or major foreign operational hubs is inconclusive based on available public sources.

Leadership & Governance

SeaStar Medical’s leadership team combines experience in biotechnology, medical devices, healthcare commercialization, and public company governance. The company’s strategic approach has emphasized clinical validation, regulatory execution, and the advancement of immunomodulatory therapies for critically ill populations. Governance oversight is provided through executive leadership and the company’s board structure consistent with U.S. public company requirements.

Key executives and leadership figures include:

• Eric Schlorff – Chief Executive Officer
• David Green – Chief Financial Officer
• Kevin Chung, MD – Chief Medical Officer
• Kurt Kruger – Senior Vice President of Operations

Public company disclosures and leadership communications have consistently emphasized innovation in critical care medicine, disciplined regulatory advancement, and the pursuit of therapies intended to improve outcomes for patients with severe inflammatory conditions.